Source comparison
Growth Hormone Release Pathways — GHRH Versus Ghrelin Receptors
Growth hormone secretion is controlled by two independent receptor pathways in the anterior pituitary. GHRH receptors, when activated, stimulate somatotroph cells to synthesize and release GH. But the duration of that release is normally limited by rapid enzym
This comparison does not assign a generated winner or score.
- Growth hormone secretion is controlled by two independent receptor pathways in the anterior pituitary. GHRH receptors, when activated, stimulate somatotroph cells to synthesize and release GH. But the duration of that release is normally limited by rapid enzymatic degradation of native GHRH, which has a half-life under 7 minutes in human plasma. CJC-1295 No DAC extends this window by incorporating four amino acid substitutions that confer dipeptidyl peptidase-IV (DPP-IV) resistance, extending the functional half-life to approximately 30 minutes while preserving full GHRH receptor affinity.
- Ghrelin receptors (officially termed growth hormone secretagogue receptor 1a, or GHS-R1a) represent a separate pathway. Ipamorelin binds to GHS-R1a with high selectivity, triggering GH release through intracellular calcium mobilization and cAMP signaling. Pathways distinct from GHRH-mediated mechanisms. Critically, ipamorelin does not activate the subtypes of ghrelin receptors responsible for ACTH (cortisol precursor) or prolactin secretion, which distinguishes it from older secretagogues like GHRP-6 or hexarelin. A 2008 dose-escalation study in healthy volunteers confirmed ipamorelin's selectivity: doses up to 200 mcg produced no statistically significant increase in cortisol or prolactin, while GH levels rose by 13–17 ng/mL above baseline.
- Here's the honest answer: most peptide protocols combine these two compounds because they act on separate receptor systems, which theoretically allows additive or synergistic GH elevation without redundancy. The mechanistic logic is sound. But direct human studies quantifying the magnitude of synergy versus independent effects remain limited as of 2026.